Dashboard
Poor long term growth as Net Sales has grown by an annual rate of 1.23% and Operating profit at 34.47% over the last 5 years
The company has declared Negative results for the last 6 consecutive quarters
With ROE of 4.51%, it has a fair valuation with a 1.18 Price to Book Value
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,185 Million (Large Cap)
26.00
NA
4.64%
-0.43
4.51%
1.18
Total Returns (Price + Dividend) 
By-health Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

By-health Co., Ltd. Hits Day High with Strong Intraday Performance
By-health Co., a key player in the Pharmaceuticals & Biotechnology sector, experienced notable stock activity on October 15, 2025. The company has shown a weekly increase but faces challenges with flat monthly performance and a decline over the past year. It maintains a market cap of CNY 13,185 million and a dividend yield of 4.64%.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 1 Foreign Institutions (0.02%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is -11.62% vs -20.93% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 84.18% vs -68.79% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -27.17% vs 19.64% in Dec 2023
YoY Growth in year ended Dec 2024 is -63.58% vs 26.04% in Dec 2023






